TITLE

Hepatitis A: The Vaccine Dividend

AUTHOR(S)
Dienstag, Jules L.
PUB. DATE
May 2008
SOURCE
Journal of Infectious Diseases;5/1/2008, Vol. 197 Issue 9, p1220
SOURCE TYPE
Academic Journal
DOC. TYPE
Editorial
ABSTRACT
The author reflects on the effects of hepatitis A vaccination in the U.S. He stated that the study of Vorg has showed a 32% decrease of death related to hepatitis A between the prevaccine period of 1990-1995 and the post-vaccination recommendation period of 2000-2004. However, the proportion of hepatitis A deaths with underlying chronic liver disease (CLD) has increased from 44% in 1999 to 67% in 2004, despite the reduction in hepatitis A incidence during the postvaccination era.
ACCESSION #
32039534

 

Related Articles

  • Hepatitis B Vaccination Coverage Among Adults -- United States, 2004.  // MMWR: Morbidity & Mortality Weekly Report;5/12/2006, Vol. 55 Issue 18, p509 

    The article presents a study regarding the vaccination coverage among adults with hepatitis B virus (HBV) in the United States. The National Health Interview Survey (NHIS) reports that during 2004, 34.6% of adults aging from 18-49 years are receiving hepatitis B vaccine including 45.4% of adults...

  • Impact of Thimerosal-Related Changes in Hepatitis B Vaccine Birth-Dose Recommendations on Childhood Vaccination Coverage. Luman, Elizabeth T.; Fiore, Anthony E.; Strine, Tara W.; Barker, Lawrence E. // JAMA: Journal of the American Medical Association;5/19/2004, Vol. 291 Issue 19, p2351 

    Context In July 1999, the longstanding preference to begin hepatitis B vaccination of all US infants at birth was temporarily suspended because of concerns about exposure to mercury contained in the vaccine preservative thimerosal. The suspension was lifted in September 1999 when...

  • Can Specific Heterologous Immunity Boost Hepatitis B Vaccine Responses? Diepolder, Helmut M. // Journal of Infectious Diseases;8/1/2008, Vol. 198 Issue 3, p297 

    The article discusses the effect of a specific heterologous immunity in boosting Hepatitis B Vaccinne responses. The currently licensed hepatitis B vaccines are highly effective and induce protective antibody titers in 95% of vaccines after three immunizations. Moreover, immunogenicity of the...

  • Excellent Response Rate to a Double Dose of the Combined Hepatitis A and B Vaccine in Previous Nonresponders to Hepatitis B Vaccine. Cardell, Kristina; Åkerlind, Britt; Sällberg, Matti; Frydén, Aril // Journal of Infectious Diseases;8/1/2008, Vol. 198 Issue 3, p299 

    Background. Hepatitis B vaccine has been shown to be highly efficient in preventing hepatitis B. However, 5%-10% of individuals fail to develop protective levels (⩾10 mIU/mL) of antibodies to hepatitis B surface antigen (anti-HBs) and are considered to be nonresponders. Methods. A total of...

  • Liver cirrhosis: Child–Pugh grading of cases seen in Nigeria. Ndububa, D. A.; Ojo, O. S.; Aladegbaiye, A. O.; Adebayo, R. A.; Adetiloye, V. A.; Durosinmi, M. A. // Tropical Doctor;Jul2005, Vol. 35 Issue 3, p169 

    Child–Pugh grading is an important determinant of treatment options, surgical interventions and prognosis in chronic liver disease. Sixty-four liver cirrhosis patients (49 men, 15 women) seen at Ile-Ife, Nigeria were graded according to the Child–Pugh parameters. Only one (1.6%)...

  • In this Issue.  // Kidney International;Feb2010, Vol. 77 Issue 3, p169 

    The article discusses various reports published within the issue, including "Lithium and Renal Failure Revisited," by Bendz et al, "Hepatitis B Vaccine," by Surquin et al and "Aging and Proteinuria in Mice," by Tsaih et al.

  • Hepatitis B Vaccination: Long-Term Follow-up of the Immune Response of Preterm Infants and Comparison of Two Vaccination Protocols. Linder, N.; Vishne, T. H.; Levin, E.; Handsher, R.; Fink-Kremer, I.; Waldman, D.; Levine, A.; Ashkenazi, S.; Sirota, L. // Infection;Jun2002, Vol. 30 Issue 3, p136 

    Background: We conducted a 3-year follow-up study of long-term antibody persistence following vaccination of low-risk preterm infants with recombinant hepatitis B vaccine (HBV). Two three-dose protocols were compared: vaccination beginning within 24 h of birth to initial, vaccination delayed...

  • The relevance of Japan's hepatitis vaccine policy to national Hepatitis B prevention and control. Takahashi, Kenzo; Kobayashi, Jun; Sugiura, Yasuo // Journal of Public Health Policy;Feb2012, Vol. 33 Issue 1, p136 

    The article reports on the significance of the hepatitis vaccine in Japan to the national prevention and control of Hepatitis B. It states that Japan had been administering hepatitis B project for the prevention of mother-to-infant infection and adopted a nationwide strategy to prevent...

  • Vertex: dipping into the non-responders pool.  // PharmaWatch: Monthly Review;Nov2005, Vol. 4 Issue 11, p34 

    The article reports that Vertex Pharmaceuticals Inc. has unveiled encouraging results from a phase lb trial evaluating its vaccine, VX-950 in hepatitis C. Hepatitis C virus (HCV) protease inhibitors led by VX-950 are currently perceived as the most promising drug in the battle against chronic...

  • The life-saving shot. Highfield, Roger // New Scientist;8/8/2009, Vol. 203 Issue 2720, p23 

    The article discusses the efficacy of vaccination in preventing deaths from hepatitis B and liver cancer. In China, a drop in prevalence of around 15%to fewer than 1% has been reported since the introduction of national vaccination programmes. However, the incidence of liver cancer in Taiwan...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics